welcome first quarter result conference call today conference record time would like turn conference power vice president investor relation please ahead power vice president investor relation thank good morning everyone thank join today first quarter earn call join morning prepare remark board chair chief executive officer chief financial officer also participate today call chief commercialization officer chief medical officer head global drug development post slide follow along today remark start read forward look statement call make statement company future plan prospect constitute forward look statement actual result differ materially indicate forward look statement result various important factor include discuss company file forward look statement represent estimate today rely upon represent estimate future date specifically disclaim obligation update forward look statement even estimate change also focus comment financial measure adjust exclude certain specify item reconciliation financial measure comparable measure available board chair chief executive officer thank good morning everyone start proud continue strong execution global pandemic significant progress make strategy want recognize thank global employee hard work resilience challenge time turn slide start year strategy grow business renew portfolio decade first quarter deliver strong result consistent strategy successfully grow revenue launch medicine indication continue advance pipeline start financial performance revenue grow despite impact relate pattern last year quarter strong sale context relate dynamic product base continue strength business affirm full year guidance accelerate renewal portfolio advance across four therapeutic area regulatory approval clinical readout build diversify younger portfolio fuel growth decade beyond although remain uncertainty recovery evolve actively plan return colleague workplace prioritize plan fully bring sale back field condition allow support line product launch turn execution scorecard slide please already make solid progress across board specifically oncology first agent first line approval gastric cancer combine opportunity metastatic adjuvant esophageal cancer become lead medicine patient early advance cancer strengthen growth long term sustainability franchise positive phase clinical trial relatlimab company three prove mechanism build leadership position melanoma plus regimen demonstrate clinically meaningful benefit monotherapy second agent great accomplishment know high efficacy monotherapy first line melanoma great news patient advance melanoma look forward present data beyond eight near term launch successfully hematology make great progress cell therapy franchise approval product launch also progress happen immunology present phase data deucrava expect file later year important medicine patient company significant revenue potential know deucrava first class selective inhibitor potential become oral standard care moderate severe psoriasis also broader potential treat disease psoriatic arthritis lupus stage pipeline initiate phase study cendakimab eosinophilic esophagitis file mavacamten date early next year give potential early stage pipeline multiple asset across therapeutic area modality include protein cell therapy next generation biologics plan depth session sometime fall update progress within pipeline support long term potential company turn slide execution company remarkable reinforce confidence ability capitalize potential future growth remain focus grow business importantly expect product constitute business roughly third continue business come launch portfolio believe launch portfolio significant potential billion billion risk adjust sale potential include potential medicine could come early stage pipeline close confident establish strong foundation future growth strength execution promise launch opportunity ahead breadth pipeline strength balance sheet position turn walk financials chief financial officer thank thank join call today like start strong line performance slide continue sale growth drive strong operational performance exclude approximately million relate pattern experience last year underlie sale growth strong exclude benefit foreign exchange continue execute operate mostly virtual environment provide additional color performance brand launch start slide another strong quarter global sale despite unwind fourth quarter inventory build approximately million relate build experience time last year first quarter sale increase versus prior year drive strong demand total prescription strength position first quarter sale also include impact onetime true approximately million relate coverage look toward second half year expect similar dynamic coverage prior year remain optimistic continue growth opportunity since brand volume return prepandemic level accelerate switch internationally sale remain strong grow versus prior year continue multiple market internationally significant room grow remain please execution around world expect continue grow share within grow class turn slide relate first quarter performance first line lung share remain double digit within eligible population launch plus indication first line renal build strong position space significant uptake unfavorable segment plus indicate impact quarter resurgence virus earlier year impact office infusion remain confident return growth year support growth also please recent approval plus chemo first regimen approve first line gastric cancer look forward launch additional indication early stage disease across esophageal muscle invasive bladder cancer expect contribute growth later year additionally multiple opportunity future growth include treatment first line esophageal cancer announce primary endpoint trial read time outside sale favorable effect foreign exchange encourage strong adoption approval increase reimbursement include regimen regimen dynamic offset second line indication impact look forward expect expand several additional indication currently review remain excite growth outlook move slide like touch line multiple myeloma portfolio sale flat growth offset expect work last quarter inventory build also expect seasonality experience patient enter coverage early year outside increase primarily foreign exchange strong demand triplet base therapy offset approximate million combine impact inventory build tender last year result increase globally global revenue drive overall strong demand triplet base regimen earlier line want spend minute share progress make quarter recent launch slide launch contribute million sale quarter start generate million first quarter continue please launch uptake patient start continue transition initial bolus underlie demand market impact remain focus continue drive start patient earlier treatment journey initial launch international market continue market globally course year receive reimbursement move continue good traction establish brand modulator choice multiple sclerosis positive initial prescribe experience translate repeat script also encourage patient convert commercial supply quicker rate beyond multiple sclerosis look forward launch ulcerative colitis approval expect outside please launch several market continue secure reimbursement additional market year progress market authorization application ulcerative colitis also remain review approval expect toward year turn continue encourage launch remain focus establish profile first oral treatment demonstrate overall survival benefit first line maintenance physician feedback awareness positive focus remain shape establish maintenance segment treatment paradigm know take time outside recently receive positive opinion approval expect year turn newly establish cell therapy franchise slide excite launch differentiate cell therapy patient follow recent approval large cell lymphoma multiple myeloma first regard best class early launch message around efficacy outpatient utilization resonate high awareness among also please rapid activation treatment site approximately site activate patient already recently infuse relate excite first ever approve patient highly refractory multiple myeloma week launch encourage enthusiasm hear customer treatment also real opportunity synergy combine execution therapy able leverage exist grow site footprint important medicine priority expand site footprint rapid account activation maximize differentiate profile ensure seamless customer experience take item slide first gross margin continue largely function product first quarter gross margin rate impact strength addition foreign exchange operate expense reflect continue investment multiple launch across various therapeutic area relate rate effective rate quarter reflect earn quarter switch gear balance sheet capital allocation slide liquidity position remain strong approximately billion cash marketable security include strong cash flow operation nearly billion quarter regard capital allocation business development remain priority company continue evaluate opportunity complement internal innovation regard debt reduction quarter demonstrate commitment strong investment grade credit accelerate repayment debt billion tender redemption also commit return cash shareholder dividend share repurchase recall increase share repurchase authorization billion start year plan back billion billion share year first quarter already repurchase billion toward goal remain opportunistic year progress turn guidance slide follow quarter performance reaffirm guidance year reflect significant growth last year business remain resilient launch opportunity come fruition please performance also considerable progress make execute launch advance pipeline like turn call back power vice president investor relation great thank much first question please